The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Acinetobacter Infections Treatment-Global Market Insights and Sales Trends 2025
Synopsis
Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.
Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.
Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.
The global Acinetobacter Infections Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Acinetobacter Infections Treatment in various end use industries. The expanding demands from the ETX2514, Nacubactam RG6080, Arenicin and VXD-001, are propelling Acinetobacter Infections Treatment market. Sulbactam, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Carbapenems segment is estimated at % CAGR for the next seven-year period.
In the American market, Major manufacturers include Entasis Therapeutics, Roche, Adenium Biotech, Vaxdyn, Hsiri Therapeutics, Aridis Pharmaceuticals, and Legochem Biosciences, Atterx Biotherapeutics, Achaogen, Peptilogics, Sealife Pharma, Shionogi, Techulon and Tetraphase Pharmaceuticals, among others. Entasis Therapeutics, Roche and Adenium Biotech are the top 3 players of Acinetobacter Infections Treatment, with about 66% market shares.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Pipeline. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Acinetobacter Infections Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Acinetobacter Infections Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Acinetobacter Infections Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Acinetobacter Infections Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Acinetobacter Infections Treatment covered in this report include Entasis Therapeutics, Roche, Adenium Biotech, Vaxdyn, Hsiri Therapeutics, Aridis Pharmaceuticals, LegoChem Biosciences, Atterx Biotherapeutics and Achaogen, etc.
The global Acinetobacter Infections Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Entasis Therapeutics
Roche
Adenium Biotech
Vaxdyn
Hsiri Therapeutics
Aridis Pharmaceuticals
LegoChem Biosciences
Atterx Biotherapeutics
Achaogen
Peptilogics
Sealife PHARMA
Shionogi
Techulon
Tetraphase Pharmaceuticals
Global Acinetobacter Infections Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Acinetobacter Infections Treatment market, Segment by Type:
Sulbactam
Carbapenems
Aminoglycosides
Polymyxins
Tetracyclines
Others
Global Acinetobacter Infections Treatment market, by Pipeline
ETX2514
Nacubactam RG6080
Arenicin
VXD-001
Small Molecule Antibiotic
AR-401 mAB
LCB01-0371 (PO)
GN-4474
Antibacterial Antibody
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Pipeline, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Acinetobacter Infections Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.
Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.
Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.
The global Acinetobacter Infections Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Acinetobacter Infections Treatment in various end use industries. The expanding demands from the ETX2514, Nacubactam RG6080, Arenicin and VXD-001, are propelling Acinetobacter Infections Treatment market. Sulbactam, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Carbapenems segment is estimated at % CAGR for the next seven-year period.
In the American market, Major manufacturers include Entasis Therapeutics, Roche, Adenium Biotech, Vaxdyn, Hsiri Therapeutics, Aridis Pharmaceuticals, and Legochem Biosciences, Atterx Biotherapeutics, Achaogen, Peptilogics, Sealife Pharma, Shionogi, Techulon and Tetraphase Pharmaceuticals, among others. Entasis Therapeutics, Roche and Adenium Biotech are the top 3 players of Acinetobacter Infections Treatment, with about 66% market shares.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Pipeline. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Acinetobacter Infections Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Acinetobacter Infections Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Acinetobacter Infections Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Acinetobacter Infections Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Acinetobacter Infections Treatment covered in this report include Entasis Therapeutics, Roche, Adenium Biotech, Vaxdyn, Hsiri Therapeutics, Aridis Pharmaceuticals, LegoChem Biosciences, Atterx Biotherapeutics and Achaogen, etc.
The global Acinetobacter Infections Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Entasis Therapeutics
Roche
Adenium Biotech
Vaxdyn
Hsiri Therapeutics
Aridis Pharmaceuticals
LegoChem Biosciences
Atterx Biotherapeutics
Achaogen
Peptilogics
Sealife PHARMA
Shionogi
Techulon
Tetraphase Pharmaceuticals
Global Acinetobacter Infections Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Acinetobacter Infections Treatment market, Segment by Type:
Sulbactam
Carbapenems
Aminoglycosides
Polymyxins
Tetracyclines
Others
Global Acinetobacter Infections Treatment market, by Pipeline
ETX2514
Nacubactam RG6080
Arenicin
VXD-001
Small Molecule Antibiotic
AR-401 mAB
LCB01-0371 (PO)
GN-4474
Antibacterial Antibody
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Pipeline, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Acinetobacter Infections Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Acinetobacter Infections Treatment
1.1 Acinetobacter Infections Treatment Market Overview
1.1.1 Acinetobacter Infections Treatment Product Scope
1.1.2 Acinetobacter Infections Treatment Market Status and Outlook
1.2 Global Acinetobacter Infections Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Acinetobacter Infections Treatment Market Size by Region (2018-2029)
1.4 Global Acinetobacter Infections Treatment Historic Market Size by Region (2018-2023)
1.5 Global Acinetobacter Infections Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Acinetobacter Infections Treatment Market Size (2018-2029)
1.6.1 North America Acinetobacter Infections Treatment Market Size (2018-2029)
1.6.2 Europe Acinetobacter Infections Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Acinetobacter Infections Treatment Market Size (2018-2029)
1.6.4 Latin America Acinetobacter Infections Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Acinetobacter Infections Treatment Market Size (2018-2029)
2 Acinetobacter Infections Treatment Market by Type
2.1 Introduction
2.1.1 Sulbactam
2.1.2 Carbapenems
2.1.3 Aminoglycosides
2.1.4 Polymyxins
2.1.5 Tetracyclines
2.1.6 Others
2.2 Global Acinetobacter Infections Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Acinetobacter Infections Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Acinetobacter Infections Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Acinetobacter Infections Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Acinetobacter Infections Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Acinetobacter Infections Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Acinetobacter Infections Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Acinetobacter Infections Treatment Revenue Breakdown by Type (2018-2029)
3 Acinetobacter Infections Treatment Market Overview by Pipeline
3.1 Introduction
3.1.1 ETX2514
3.1.2 Nacubactam RG6080
3.1.3 Arenicin
3.1.4 VXD-001
3.1.5 Small Molecule Antibiotic
3.1.6 AR-401 mAB
3.1.7 LCB01-0371 (PO)
3.1.8 GN-4474
3.1.9 Antibacterial Antibody
3.1.10 Others
3.2 Global Acinetobacter Infections Treatment Market Size by Pipeline: 2018 VS 2022 VS 2029
3.2.1 Global Acinetobacter Infections Treatment Historic Market Size by Pipeline (2018-2023)
3.2.2 Global Acinetobacter Infections Treatment Forecasted Market Size by Pipeline (2024-2029)
3.3 Key Regions Market Size by Pipeline
3.3.1 North America Acinetobacter Infections Treatment Revenue Breakdown by Pipeline (2018-2029)
3.3.2 Europe Acinetobacter Infections Treatment Revenue Breakdown by Pipeline (2018-2029)
3.3.3 Asia-Pacific Acinetobacter Infections Treatment Revenue Breakdown by Pipeline (2018-2029)
3.3.4 Latin America Acinetobacter Infections Treatment Revenue Breakdown by Pipeline (2018-2029)
3.3.5 Middle East and Africa Acinetobacter Infections Treatment Revenue Breakdown by Pipeline (2018-2029)
4 Acinetobacter Infections Treatment Competition Analysis by Players
4.1 Global Acinetobacter Infections Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Acinetobacter Infections Treatment as of 2022)
4.3 Date of Key Players Enter into Acinetobacter Infections Treatment Market
4.4 Global Top Players Acinetobacter Infections Treatment Headquarters and Area Served
4.5 Key Players Acinetobacter Infections Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Acinetobacter Infections Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Entasis Therapeutics
5.1.1 Entasis Therapeutics Profile
5.1.2 Entasis Therapeutics Main Business
5.1.3 Entasis Therapeutics Acinetobacter Infections Treatment Products, Services and Solutions
5.1.4 Entasis Therapeutics Acinetobacter Infections Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 Entasis Therapeutics Recent Developments
5.2 Roche
5.2.1 Roche Profile
5.2.2 Roche Main Business
5.2.3 Roche Acinetobacter Infections Treatment Products, Services and Solutions
5.2.4 Roche Acinetobacter Infections Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Roche Recent Developments
5.3 Adenium Biotech
5.3.1 Adenium Biotech Profile
5.3.2 Adenium Biotech Main Business
5.3.3 Adenium Biotech Acinetobacter Infections Treatment Products, Services and Solutions
5.3.4 Adenium Biotech Acinetobacter Infections Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Vaxdyn Recent Developments
5.4 Vaxdyn
5.4.1 Vaxdyn Profile
5.4.2 Vaxdyn Main Business
5.4.3 Vaxdyn Acinetobacter Infections Treatment Products, Services and Solutions
5.4.4 Vaxdyn Acinetobacter Infections Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Vaxdyn Recent Developments
5.5 Hsiri Therapeutics
5.5.1 Hsiri Therapeutics Profile
5.5.2 Hsiri Therapeutics Main Business
5.5.3 Hsiri Therapeutics Acinetobacter Infections Treatment Products, Services and Solutions
5.5.4 Hsiri Therapeutics Acinetobacter Infections Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Hsiri Therapeutics Recent Developments
5.6 Aridis Pharmaceuticals
5.6.1 Aridis Pharmaceuticals Profile
5.6.2 Aridis Pharmaceuticals Main Business
5.6.3 Aridis Pharmaceuticals Acinetobacter Infections Treatment Products, Services and Solutions
5.6.4 Aridis Pharmaceuticals Acinetobacter Infections Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Aridis Pharmaceuticals Recent Developments
5.7 LegoChem Biosciences
5.7.1 LegoChem Biosciences Profile
5.7.2 LegoChem Biosciences Main Business
5.7.3 LegoChem Biosciences Acinetobacter Infections Treatment Products, Services and Solutions
5.7.4 LegoChem Biosciences Acinetobacter Infections Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 LegoChem Biosciences Recent Developments
5.8 Atterx Biotherapeutics
5.8.1 Atterx Biotherapeutics Profile
5.8.2 Atterx Biotherapeutics Main Business
5.8.3 Atterx Biotherapeutics Acinetobacter Infections Treatment Products, Services and Solutions
5.8.4 Atterx Biotherapeutics Acinetobacter Infections Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Atterx Biotherapeutics Recent Developments
5.9 Achaogen
5.9.1 Achaogen Profile
5.9.2 Achaogen Main Business
5.9.3 Achaogen Acinetobacter Infections Treatment Products, Services and Solutions
5.9.4 Achaogen Acinetobacter Infections Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Achaogen Recent Developments
5.10 Peptilogics
5.10.1 Peptilogics Profile
5.10.2 Peptilogics Main Business
5.10.3 Peptilogics Acinetobacter Infections Treatment Products, Services and Solutions
5.10.4 Peptilogics Acinetobacter Infections Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 Peptilogics Recent Developments
5.11 Sealife PHARMA
5.11.1 Sealife PHARMA Profile
5.11.2 Sealife PHARMA Main Business
5.11.3 Sealife PHARMA Acinetobacter Infections Treatment Products, Services and Solutions
5.11.4 Sealife PHARMA Acinetobacter Infections Treatment Revenue (US$ Million) & (2018-2023)
5.11.5 Sealife PHARMA Recent Developments
5.12 Shionogi
5.12.1 Shionogi Profile
5.12.2 Shionogi Main Business
5.12.3 Shionogi Acinetobacter Infections Treatment Products, Services and Solutions
5.12.4 Shionogi Acinetobacter Infections Treatment Revenue (US$ Million) & (2018-2023)
5.12.5 Shionogi Recent Developments
5.13 Techulon
5.13.1 Techulon Profile
5.13.2 Techulon Main Business
5.13.3 Techulon Acinetobacter Infections Treatment Products, Services and Solutions
5.13.4 Techulon Acinetobacter Infections Treatment Revenue (US$ Million) & (2018-2023)
5.13.5 Techulon Recent Developments
5.14 Tetraphase Pharmaceuticals
5.14.1 Tetraphase Pharmaceuticals Profile
5.14.2 Tetraphase Pharmaceuticals Main Business
5.14.3 Tetraphase Pharmaceuticals Acinetobacter Infections Treatment Products, Services and Solutions
5.14.4 Tetraphase Pharmaceuticals Acinetobacter Infections Treatment Revenue (US$ Million) & (2018-2023)
5.14.5 Tetraphase Pharmaceuticals Recent Developments
6 North America
6.1 North America Acinetobacter Infections Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Acinetobacter Infections Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Acinetobacter Infections Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Acinetobacter Infections Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Acinetobacter Infections Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Acinetobacter Infections Treatment Market Dynamics
11.1 Acinetobacter Infections Treatment Industry Trends
11.2 Acinetobacter Infections Treatment Market Drivers
11.3 Acinetobacter Infections Treatment Market Challenges
11.4 Acinetobacter Infections Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
